Clinical Trial
Selegiline for Parkinson's disease
Affiliations
- PMID: 2105624
Item in Clipboard
Clinical Trial
Selegiline for Parkinson's disease
Am Fam Physician.
1990 Feb.
Abstract
Monoamine oxidase inhibitors that have been available in the United States are nonselective and thus act equally on peripheral and brain monoamine oxidase. Recently, selegiline, a selective monoamine oxidase inhibitor, has been approved for use in the management of Parkinson's disease. Clinical trials demonstrate that selegiline in combination with carbidopa/levodopa is effective in relieving symptoms and prolonging remission. The dosage of carbidopa/levodopa can usually be reduced, resulting in diminished side effects. Selegiline is relatively nontoxic and appears to be a valuable addition in the management of Parkinson's disease.
Similar articles
-
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.Expert Rev Neurother. 2005 Nov;5(6):811-21. doi: 10.1586/14737175.5.6.811. Expert Rev Neurother. 2005. PMID: 16274338 Review.
-
Selegiline: a second look. Six years later: too risky in Parkinson's disease.Prescrire Int. 2002 Aug;11(60):108-11. Prescrire Int. 2002. PMID: 12199263
-
[Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].Riv Neurol. 1985 Jan-Feb;55(1):46-52. Riv Neurol. 1985. PMID: 3927468 Review. Italian. No abstract available.
-
R-(-)-deprenyl as a possible protective agent in Parkinson's disease.J Neural Transm Suppl. 1987;25:69-79. J Neural Transm Suppl. 1987. PMID: 3123606 Clinical Trial.
-
DATATOP-study: significance of its results in the treatment of Parkinson's disease.J Neural Transm Suppl. 1995;46:391-7. J Neural Transm Suppl. 1995. PMID: 8821074 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical